Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its 'asset-centric' approach to investing. The new firm launches with the close of Medicxi Ventures 1 (MV1), a new €210m ($250m) fund that will continue focusing on asset-centric, early-stage investments in European life science programs.
Medicxi Ventures will be managed by four general partners: Francesco De Rubertis, David Grainger, Kevin Johnson and Michèle Ollier. The four previously led the life sciences practice of Index Ventures....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
